期刊文献+

胃肠肿瘤术后Tu M_2-PK含量的变化 被引量:2

Changes of Plasma M_2-PK Concentration in Gastrointestinal Cancer Patients After the Operation
暂未订购
导出
摘要 目的:探讨胃肠肿瘤根治手术后无可测量病灶患者血浆TuM2PK变化规律。方法:采用ELISA方法测定37例胃肠肿瘤根治术后无可测量病灶患者血浆TuM2PK的含量并分析。结果:血浆TuM2PK含量分别为:对照组(8.6±3.4)U/ml;术后1个月组(38.5±26.2)U/ml,术后2个月组(22.1±18.2)U/ml;术后3个月以上组(14.6±13.2)U/ml。以≥15U/ml为界,四组阳性检出率分别为0%、78.4%、48.1%、29.7%。对照组与肿瘤各组间含量差异有显著性(P<0.01)。结论:胃肠肿瘤根治手术后无可测量病灶时血浆TuM2PK浓度与手术时间呈负相关。动态检测血浆TuM2PK对于胃肠肿瘤术后的诊断、治疗效果和预后评价具有应用价值,是一个更为理想的、新的、敏感的广谱肿瘤标记物。 Objective To investigate the clinical value of the plasma M2-PK concentration changes changes in post-operative gastrointestinal cancer patients. Method M2-PK levels were determined in EDTA anti-coagulated plasma from 37 post-operative gastrointestinal cancer patients and 32 healthy control individuals by ELISA. Results The tumor M2-PK-concentrations were (8.6±3.4)U/ml, (8.5±26.2)U/ml, (22.1±18.2)U/ml and (14.1±13.2)U/ml for the control group and the post-oporative groups in 1 month, 2 months and beyond 3 months respectively. The cut-off value of 15 U/ml taken, the positive rate of the five groups were 0%, 78.4%, 48.1% and 29.7% respectively. Conclusion Tumor relevant M2-PK concentration has negative correlation with time after gastrointestinal tumor operation. For the post-operative gastrointestinal cancer patientst of follow up the plasma M2-PK concertration has important value in the diagnosis, evaluation of treatment effiency and the prognosis, M2-PK might provide to be an ideal, novel and sensitive tumor marker broady used in the future.
出处 《实用医技杂志》 2006年第3期350-352,共3页 Journal of Practical Medical Techniques
关键词 肿瘤标记物 M2-PK 胃癌 肠癌 Tumor marker M2-PK Gastrointestinal cancer
  • 相关文献

参考文献1

二级参考文献10

  • 1郭健.一种新的肿瘤标志物Tu M2-PK.http://www.clinet.com.cn/dynamic/expert/2001022004.,.
  • 2Sybille MAZURE, Wemer ZWERSCHKE, Pidder JANSEN-DüRR ,et al. Role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J ,2001 ; 356 : 247.
  • 3Eigenbrodt E, Kallinowski F, Ott M,et al. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res,1998 ;18(5A) :3267.
  • 4Mazurek S, Grimm H, Boschek CB, et al. Pyruvate kinase type M2 :a crossroad in the tumor metabolome. Br J Nutr,2002 ; ( 1 ) :23.
  • 5Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Research , 1999 ;19:2753.
  • 6Oromek GM, Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumor M2(Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Research, 1999;19:2599.
  • 7Cerwenka H, Aigner R, Bacher H, et al. TUM2-PK (pyruvate kinase type tumor M2), CA 19-9 and CEA in patients with benign,malignant and metastasizing pancreatic lesions. Anticancer Research,1999;19:849.
  • 8Lamerts R: CA 72-4. In: L. Thomas: Labor and diagnose. Med.Verlagsgesellsehaft Marburg, 1995.
  • 9Hardt P. D, Ngoumou B, et al. A promising tumor marker in the of gastrointestinal cancer. Antieaneer Research , 1999 ; 19 : 2583.
  • 10Maurizio Venlrucci, Antonio Cipolla, Chiara Racchini, et al. Plasma Tu M2-PK determination for the diagnosis of pancreatic cancer.Anticancer Research, 1999 ; 19 : 2599.

共引文献2

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部